Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication

Opioid-Related Disorders Clinical Trial

Official title:

Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02660619
• Other study ID #: Observational Study 3033-5
• Secondary ID: Study 3033-5
• Status: Completed
• Start date: November 17, 2015
• Est. completion date: November 28, 2017

Study information

• Verified date: June 2020
• Source: Member Companies of the Opioid PMR Consortium
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose is to validate the PRISM-5-Op as a measurement of prescription opioid substance use disorder.

Description:

"Based on a review of the literature, the Food and Drug Administration (FDA) concluded that more data are needed regarding the serious risks of misuse, abuse, addiction, overdose, and death associated with the long-term use of extended release/long acting (ER/LA) opioid analgesics. Thus, the FDA is requiring that ER/LA opioid analgesic drug sponsors conduct post-marketing studies to assess these risks. The present study, PMR Study #2065-2, focuses on addiction, and addresses the FDA requirement to conduct a validation study of the measure of addiction that will be used in PMR Study #2065-1.

The primary objective for Study 2b is to validate PRISM-5-Op measures of DSM-5 prescription opioid SUD/addiction in patients who have, or have had, a prescription for opioids for at least 30 days to treat chronic pain"

Recruitment information / eligibility

• Status: Completed
• Enrollment: 606
• Est. completion date: November 28, 2017
• Est. primary completion date: November 28, 2017
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Has or has had a prescription for opioids for chronic pain for at least 30 days

2. Age 18 years or older and English-speaking

3. Willing and able to provide informed consent"

Exclusion Criteria:

1. Patient has a hearing or vision impairment that would preclude an interview or completion of self-administered questionnaires

2. Patient too cognitively impaired to give informed consent or participate in the evaluations.

Related Conditions & MeSH terms

• Behavior, Addictive
• Drug Abuse
• Narcotic Abuse
• Opiate Addiction
• Opioid-Related Disorders
• Substance-Related Disorders

Intervention

Other:
• Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Member Companies of the Opioid PMR Consortium	Columbia University, Research Foundation for Mental Hygiene, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnoses of Addiction to Prescription Opioids via PRISM-5-Op	PRISM-5-Op diagnoses of DSM-5 SUD/addiction to prescription opioids. These diagnoses will be in two forms: unadjusted, meaning that the criteria will be rated positive if present without regard to the intent of the behavior, and adjusted, i.e., that criteria will be rated positive only if structured evaluation indicates that they represent addiction indicators (non-therapeutic intent) rather than treatment of pain (therapeutic intent).	Up to 14 days (reliability determined by re-interviews 1-14 days after first interview)